Revolutionizing Disease Diagnosis and Treatment with Adaptive Biotechnologies’ Immune Medicine Platform

Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Scheduled for April 2, 2024

Adaptive Biotechnologies Corporation, a biotechnology company listed on the Nasdaq under the ticker symbol ADPT, is dedicated to revolutionizing disease diagnosis and treatment through the use of the adaptive immune system. The company has recently announced that it will be hosting a business update conference call and webcast on Tuesday, April 2, 2024, after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The live audio of the webcast will be available on the “Investors” section of the company website at www.adaptivebiotech.com.

Adaptive Biotechnologies believes that the adaptive immune system is a powerful tool for diagnosing and treating diseases but has not been fully utilized due to challenges in decoding it. The company’s immune medicine platform enables this decoding with scale, precision, and speed by harnessing the biology of the adaptive immune system to develop personalized immune-driven clinical products for each patient. In two main areas – Minimal Residual Disease (MRD) and Immune Medicine – Adaptive Biotechnologies collaborates with biopharmaceutical companies, informs drug development, and develops clinical diagnostics to aid in diagnosing, monitoring, and treating diseases such as cancer, autoimmune disorders, and infectious diseases.

For media inquiries contact Erica Jones at media@adaptivebiotech.com or for investor inquiries contact Karina Calzadilla at investors@adaptivebiotech.com

Leave a Reply